



University of Tasmania announces opening of Pfizer Analytical Research Centre at the University of Tasmania, Hobart, Tasmania, Australia

The University of Tasmania, Hobart, Tasmania, Australia is pleased to announce the establishment of a new research centre targeting innovation and productivity in Pharmaceutical Analytical Sciences. The centre is the result of a collaboration between Pfizer, the world's largest research-based pharmaceutical company, and the University of Tasmania.

The collaboration creates a centre of excellence for the development of novel pharmaceutical analytical methods by combining the expertise of the Australian Centre for Research on Separation Science (ACROSS) at the School of Chemistry, University of Tasmania (UTAS) with that of Pfizer scientists. The centre, which has been named the University of Tasmania Pfizer Analytical Research Centre (PARC), will be based at the University of Tasmania's Hobart Campus.

PARC is a multidisciplinary collaboration which aims to generate high-throughput, faster, and smarter analytical systems for pharmaceutical analysis and drug discovery, to introduce novel approaches to pharmaceutical analysis, such as green chromatography, and to advance innovative ideas and concepts for analytical work into the 21st century. The UTAS PARC centre complements a separate PARC collaboration set up at the Ghent University, Belgium, established in 2003 under the direction of Professor Pat Sandra.

Commenting on the collaboration, Professor Paul Haddad, the University of Tasmania PARC Director, said:

"The establishment of PARC within ACROSS at UTAS is a significant initiative for us. This centre provides exciting opportunities to perform cutting-edge research into pharmaceutical separation science with input from one of the world's leading research-based pharmaceutical companies. The collaboration will provide a direct link between experts in analytical chemistry and the pharmaceutical industry. This will encourage innovative work in this field through the development of faster, smarter and smaller analytical tools."

Under the terms of the 4 year agreement, Pfizer will support post-doctoral staff who will work together with Ph.D. and undergraduate students on jointly agreed research projects.

Pfizer is a participant in the Australian Government's Pharmaceuticals Partnership Program (P3). Under P3, Pfizer is committed to increasing its Research and Development activities in Australia.

For more information, contact:

1. Professor Paul Haddad, Director, Australian Centre for Research On Separation Science (ACROSS), School of Chemistry, University of Tasmania, Hobart, Tasmania, 7001, Australia, Email: Paul.Haddad@utas.edu.au, Web: [Http://www.across.utas.edu.au](http://www.across.utas.edu.au)
2. Dr Greg Dicoski, Deputy Director, Australian Centre for Research On Separation Science (ACROSS), School of Chemistry, University of Tasmania, Hobart, Tasmania, 7001, Australia, Email: Greg.Dicoski@utas.edu.au, Web: [Http://www.across.utas.edu.au](http://www.across.utas.edu.au)
3. Adrian Dolahenty, Media Communications Manager, Public Affairs and Policy, Pfizer Australia
Phone: 61 2 9850 3488

